News

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...
Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...
Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...
However, there was big news this week that just might alter Novo Nordisk's trajectory somewhat. Look out, Ozempic and Wegovy: Eli Lilly (LLY 0.91%) is bringing a new weight-loss drug to town.
business Health Care. Eli Lilly’s new weight loss drug could drive down prices of Wegovy and Ozempic The Danish drugmaker’s Zepbound will undercut its rivals’ pricing by 21% but still cost ...
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...